| 12202836 |
Bicyclic-fused heteroaryl or aryl compounds |
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth +18 more |
2025-01-21 |
|
| 11702424 |
Bicyclic-fused heteroaryl or aryl compounds |
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth +18 more |
2023-07-18 |
$390,606,000 |
| 10793579 |
Bicyclic-fused heteroaryl or aryl compounds |
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth +18 more |
2020-10-06 |
$629,973,000 |
| 10766904 |
Bicyclic heteroaryl derivatives as CFTR potentiators |
Joseph Walter Strohbach, David Christopher Limburg, Atli Thorarensen, John James Mousseau, Rajiah Aldrin Denny +2 more |
2020-09-08 |
|
| 10494374 |
Pyrrolopyrimidines as CFTR potentiators |
Joseph Walter Strohbach, David Christopher Limburg, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf +3 more |
2019-12-03 |
|
| 10377762 |
Bicyclic heteroaryl derivatives as CFTR potentiators |
Joseph Walter Strohbach, David Christopher Limburg, Atli Thorarensen, John James Mousseau, Rajiah Aldrin Denny +2 more |
2019-08-13 |
|
| 10329302 |
Bicyclic-fused heteroaryl or aryl compounds |
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth +18 more |
2019-06-25 |
$317,230,000 |
| 10316018 |
Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators |
Katherine Lin Lee, Christophe Philippe Allais, Christoph Martin Dehnhardt, Lori Krim Gavrin, Seungil Han +10 more |
2019-06-11 |
$297,650,000 |
| 10308615 |
Heterocyclic compounds as inhibitors of Vanin-1 enzyme |
Agustin Casimiro-Garcia, Jeffrey Scott Condon, Andrew Christopher Flick, Ariamala Gopalsamy, Steven J. Kirincich +4 more |
2019-06-04 |
$869,926,000 |
| 10301315 |
Pyrrolopyrimidines as CFTR potentiators |
Joseph Walter Strohbach, David Christopher Limburg, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf +3 more |
2019-05-28 |
|
| 10208053 |
Bicyclic heteroaryl derivatives as CFTR potentiators |
Joseph Walter Strohbach, David Christopher Limburg, Atli Thorarensen, John James Mousseau, Rajiah Aldrin Denny +2 more |
2019-02-19 |
|
| 10174000 |
Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators |
Katherine Lin Lee, Christophe Philippe Allais, Christoph Martin Dehnhardt, Lori Krim Gavrin, Seungil Han +10 more |
2019-01-08 |
$262,548,000 |
| 10131670 |
Bicyclic heteroaryl derivatives as CFTR potentiators |
Joseph Walter Strohbach, David Christopher Limburg, Atli Thorarensen, John James Mousseau, Rajiah Aldrin Denny +2 more |
2018-11-20 |
|
| 9879022 |
Bicyclic-fused heteroaryl or aryl compounds |
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth +18 more |
2018-01-30 |
$267,454,000 |
| 9458168 |
Bicyclic-fused heteroaryl or aryl compounds |
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth +15 more |
2016-10-04 |
$808,860,000 |
| 8076356 |
Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors |
David S. Millan, Russell Andrew Lewthwaite, Christopher Phillips |
2011-12-13 |
$719,179,000 |
| 7557121 |
Tetrahydronaphthyridine derivatives |
Graham Lunn, Ross Sinclair Strang |
2009-07-07 |
$254,361,000 |
| 7511057 |
Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors |
David S. Millan, Russell Andrew Lewthwaite, Christopher Phillips |
2009-03-31 |
$563,080,000 |
| 7176311 |
Process for preparing pharmaceutically active compounds |
Mark Edward Bunnage, Keith M. DeVries, Laurence James Harris, Philip Charles Levett, Joanna Teresa Negri +2 more |
2007-02-13 |
$114,373,000 |
| 7153870 |
Nicotinamide derivatives useful as PDE4 inhibitors |
— |
2006-12-26 |
$286,845,000 |
| 7060717 |
Nicotinamide derivatives useful as PDE4 inhibitors |
Simon Bailey, Elisabeth Colette Louise Gautier, Alan John Henderson, Thomas Victor Magee, Anthony Marfat +3 more |
2006-06-13 |
$276,459,000 |
| 7056934 |
Nicotinamide derivatives useful as PDE4 inhibitors |
Mark Edward Bunnage |
2006-06-06 |
$125,956,000 |
| 6949573 |
Nicotinamide derivatives useful as PDE4 inhibitors |
Simon Bailey, Elisabeth Colette Louise Gautier, Alan John Henderson, Thomas Victor Magee, Anthony Marfat +3 more |
2005-09-27 |
$119,913,000 |
| 6936619 |
Quinazolinone compounds useful in therapy |
Julian Blagg, Michael J. Fray, Mark Llewellyn Lewis, Mark Henryk Stefaniak, Alan Stobie |
2005-08-30 |
$247,137,000 |
| 6916927 |
Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
Mark Edward Bunnage, Stephen Derek Albert Street, Anthony Wood |
2005-07-12 |
$283,397,000 |
